Richard Kirkner

Rich Kirkner

Contributing Writer

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

January 12 2021

Lessons learned for Conducting Clinical Trials in Challenging Times

Clinical trials on many levels have been disrupted over the past year, and the current surge can cause further disruption as different regions and cities ...
Read More

December 16 2020

800-pound Gorilla Doesn’t Deter Investors in Ophthalmology Sector

The coronavirus pandemic became the 800-pound gorilla dragging down the economy this year, but 2020 turned out to be a stellar one for investors in ...
Read More

December 8 2020

With Hemera Deal, Janssen Continues Building Out Its Retina Portfolio: Glaucoma on the Horizon

By acquiring the rights to Hemera Biosciences’ gene therapy candidate to treat geographic atrophy – the debilitating end-stage form of dry age-related macular degeneration – ...
Read More

September 15 2020

Innovation Leaders Provide Advice for Retina Start-Ups and the People Who’d Like to Work for Them

Product development in retina is a matter of suitors. That is, people looking for the right product development team to join, and early stage companies ...
Read More

August 18 2020

Manufacturing Strategy Key to AGTC’s Next Steps for Gene Therapy Programs

As Applied Genetic Technologies Corp. takes the next steps in the development of its lead gene therapy candidate for inherited retinal disease, the company has ...
Read More

July 30 2020

Virtual ASRS Reporter’s Notebook

The American Society of Retina Specialists annual scientific meeting went virtual this year, but that didn’t diminish the multitude of reports on retina treatments in ...
Read More
New J&J Vision CMO Steps onto a Very Large Stage

May 7 2020

New J&J Vision CMO Steps onto a Very Large Stage

The stage of ophthalmic innovation has hosted a multitude of new acts, people going from established companies to start-ups and vice versa and back again, ...
Read More
Covid-19 Impact on Healthcare Company Valuations & Financings

April 22 2020

Covid-19 Impact on Healthcare Company Valuations & Financings

The turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that ...
Read More
Verana eyes adding third registry

April 2 2020

Verana eyes adding third registry

The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where ...
Read More
2020’s Potential Retina Milestones

February 26 2020

2020’s Potential Retina Milestones

As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to ...
Read More
Digging deep in the retina pipeline

November 13 2019

Digging deep in the retina pipeline

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early ...
Read More
Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

March 13 2019

Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic ...
Read More